Viatris (VTRS) Net Cash Flow Growth (3y) (2022 - 2026)
Viatris (VTRS) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -22.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -106.21% |
| Mar 31, 2026 | 37.74% |
| Dec 31, 2025 | -14.86% |
| Sep 30, 2025 | 349.65% |
| Jun 30, 2025 | -48.84% |
| Mar 31, 2025 | -62.13% |
| Dec 31, 2024 | -190.33% |
| Sep 30, 2024 | 118.49% |
| Jun 30, 2024 | 13.34% |
| Mar 31, 2024 | 63.37% |
| Dec 31, 2023 | -59.14% |
| Mar 31, 2023 | -101.97% |
| Dec 31, 2022 | 76.06% |